The Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF) and Citranvi Biosciences have signed an exclusive licensing agreement to develop vaccine technologies to prevent cytomegalovirus and Epstein-Barr virus infections.
Anti-infective therapies firm Aridis Pharmaceutical has developed an inhalable highly neutralizing monoclonal antibody (mAb) that eradicated the novel coronavirus in infected rodents.
Samsung Biologics has entered into a strategic partnership with BioEleven to develop and manufacture BN-101A, a third-generation immunotherapy to treat cancer.
Reaction Biology and 4HF Biotec announced that they are offering a new cell-based service that will give customers a comprehensive understanding of their candidates. The service will combine Reaction's ProLiFiler cell assay service with 4HF's Biomarker Analysis and Mode of Action (MoA) Finder tools
Endo will acquire all shares of BioSpecifics Technologies for $88.50 per share, or an estimated total of $540 million. As part of the acquisition, BioSpecifics will receive a royalty stream from Endo's collagenase-based therapies, including Xiaflex and Qwo, which were developed by BioSpecifics.
Developing well-characterized adeno-associated viral vectors (AAVs) is a significant obstacle for the biomanufacturing industry. A group of analytical researchers is trying to overcome this challenge by developing novel analytical methodology specifically designed for AAVs. Discuss
Precigen has been granted clearance by the U.S. Food and Drug Administration (FDA) for its UltraPorator system. The system also had a successful technology transfer to clinical sites and will be used as a manufacturing device for Precigen's investigational UltraCAR-T therapies.
Thermo Fisher Scientific has launched the Gibco CTS Rotea counterflow centrifugation system, a modular, closed cell therapy processing system for cell therapy development and manufacturing.
ImmunityBio has been authorized by the U.S. Food and Drug Administration to begin a phase I clinical trial of its hAd5-COVID-19 vaccine candidate.
Sestina Bio, a new company developing an automated synthetic biology platform, has been launched with seed funding. Sestina also is the first company to be launched from the Foresite Labs incubator.
Conferences
Cell and Gene Therapy Bioprocessing and Commercialization
October 19-22
Online
October 19-22
Online
New Applications of Synthetic Biology to Cancer Research Challenges: 2020 Virtual Jumpstart
October 26-30
Online
October 26-30
Online
Japan Analytical & Scientific Instruments Show (JASIS)
November 11-13
Chiba, Chiba Japan
November 11-13
Chiba, Chiba Japan
2020 AACC Annual Scientific Meeting & Clinical Lab Expo
December 13-17
Online
December 13-17
Online
Society for Laboratory Automation and Screening (SLAS) 2021
January 23-27, 2021
San Diego, California United States
January 23-27, 2021
San Diego, California United States
Insights
Exclusive content for Science Advisory Board members on trends and outcomes that are influencing the future of scientific research.
Communities
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Rewards
Earn points for contributing to research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Connect
